Journal
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
Volume 100, Issue 9, Pages 834-847Publisher
CANADIAN SCIENCE PUBLISHING
DOI: 10.1139/cjpp-2022-0154
Keywords
cardiac remodeling; hemodynamic overload; cardiac ECM; subcellular remodeling; pharmacotherapy of heart failure
Categories
Ask authors/readers for more resources
This article discusses the impact of changes in both cardiomyocytes and nonmyocyte extracellular matrix (ECM) on heart failure, with an emphasis on oxidative stress, inflammatory cytokines, metabolic alterations, and calcium-handling defects. It also highlights the importance of protein kinase alterations, mitochondrial calcium overload, activation of proteases and phospholipases, and changes in gene expression for subcellular remodeling in the occurrence of heart dysfunction.
Heart failure is invariably associated with cardiac hypertrophy and impaired cardiac performance. Although several drugs have been developed to delay the progression of heart failure, none of the existing interventions have shown beneficial effects in reducing morbidity and mortality. To determine specific targets for future drug development, we have discussed different mechanisms involving both cardiomyocytes and nonmyocyte extracellular matrix (ECM)) alterations for the transition of cardiac hypertrophy to heart failure as well as for the progression of heart failure. We have emphasized the role of oxidative stress, inflammatory cytokines, metabolic alterations, and Ca2+-handling defects in adverse cardiac remodeling and heart dysfunction in hypertrophied myocardium. Alterations in the regulatory process due to several protein kinases, as well as the participation of mitochondrial Ca2+ overload, activation of proteases and phospholipases, and changes in gene expression for subcellular remodeling have also been described for the occurrence of cardiac dysfunction. Association of cardiac arrhythmia with heart failure has been explained as a consequence of catecholamine oxidation products. Since these multifactorial defects in ECM and cardiomyocytes are evident in the failing heart, it is a challenge for experimental cardiologists to develop appropriate combination drug therapy for improving cardiac function in heart failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available